FIQCX
Price
$25.06
Change
+$1.68 (+7.19%)
Updated
Apr 9 closing price
Net Assets
4.47B
RGPCX
Price
$23.26
Change
+$1.93 (+9.05%)
Updated
Apr 9 closing price
Net Assets
17.55B
Ad is loading...

FIQCX vs RGPCX

Header iconFIQCX vs RGPCX Comparison
Open Charts FIQCX vs RGPCXBanner chart's image
Fidelity Advisor Asset Manager 85% Z
Price$25.06
Change+$1.68 (+7.19%)
VolumeN/A
Net Assets4.47B
American Funds Growth Portfolio R3
Price$23.26
Change+$1.93 (+9.05%)
VolumeN/A
Net Assets17.55B
FIQCX vs RGPCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FIQCX vs. RGPCX commentary
Apr 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FIQCX is a Buy and RGPCX is a Hold.

Ad is loading...
FUNDAMENTALS
Fundamentals
RGPCX has more cash in the bank: 17.6B vs. FIQCX (4.47B). FIQCX pays higher dividends than RGPCX: FIQCX (1.61) vs RGPCX (0.20). FIQCX was incepted earlier than RGPCX: FIQCX (7 years) vs RGPCX (13 years). RGPCX (1.01) is less costly to investors than FIQCX (0.57). FIQCX has a lower initial minimum investment than RGPCX: FIQCX (0) vs RGPCX (250). FIQCX annual gain was more profitable for investors over the last year : -7.52 vs. RGPCX (-11.77). FIQCX return over 5 years is better than : 46.03 vs. RGPCX (32.04).
FIQCXRGPCXFIQCX / RGPCX
Total Expense Ratio0.571.0156%
Annual Report Gross Expense Ratio0.571.0156%
Fund Existence7 years13 years-
Gain YTD-10.933-14.91873%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets4.47B17.6B25%
Annual Yield % from dividends1.610.20810%
Returns for 1 year-7.52-11.7764%
Returns for 3 years-0.03-6.241%
Returns for 5 years46.0332.04144%
Returns for 10 yearsN/A35.54-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MBCNX12.58N/A
N/A
MassMutual Blue Chip Growth R3
UBVAX67.45N/A
N/A
Undiscovered Managers Behavioral Val A
FTDZX104.73N/A
N/A
Franklin Biotechnology Discovery Adv
FOCIX13.29N/A
N/A
Fairholme Focused Income
CFMVX20.35N/A
N/A
Commerce MidCap Value